Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Exclusion Criteria

• •Acute or chronic hepatitis B or hepatitis C infection.
• •Active or recent (in prior 6 months) AIDS defining complication.
• •Any cancer or malignancy within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal or cervical dysplasia.
• •Current diagnosis of NYHA grade 3 or 4 CHF, uncontrolled angina or arrhythmias.
• •History or any features on physical examination indicative of a bleeding diathesis.
• •Received HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector.
• •Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents within 30 days prior to screening.
• •Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis.
• •Currently participating in another clinical trial or participation in such a trial within 30 days prior to screening visit.
• •Subjects who are currently taking maraviroc or have received maraviroc within 6 months prior to screening.